Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXO1
REST API REST API
Homo sapiens
FOXO1 is differentially expressed in 350 experiments: 146 organism parts: bone marrow, cerebellum, ... (144 more);, 251 disease states: normal, control, ... (249 more);, 123 cell types 409 cell lines 45 compound treatments and 73 other conditions.
Synonyms FKHR, FKH1, FOXO1A
Orthologs foxo1b (Danio rerio)   Foxo1 (Mus musculus)   foxo1a (Danio rerio)   foxo (Drosophila melanogaster)   FOXO1A (Gallus gallus)   FOXO1 (Bos taurus)   Foxo1 (Rattus norvegicus)   FOXO1 (1 of 3) (Danio rerio)   ENSCING00000016777 (Ciona intestinalis)   ENSCING00000016781 (Ciona intestinalis)   FOXO1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, pattern specification process, embryo development, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, regulation of cell proliferation, transcription, DNA-dependent, DNA bending activity, insulin receptor signaling pathway, anti-apoptosis, fibroblast growth factor receptor signaling pathway, transcription factor binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, tissue development, protein kinase binding, nucleus, transcription factor complex, nucleoplasm, response to DNA damage stimulus, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, blood vessel development, negative regulation of stress-activated MAPK cascade, positive regulation of gluconeogenesis, organ development, nerve growth factor receptor signaling pathway, endocrine pancreas development, sequence-specific DNA binding transcription factor activity, phosphatidylinositol-mediated signaling, regulation of sequence-specific DNA binding transcription factor activity, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession Q12778
Gene-Disease Assocation RHABDOMYOSARCOMA 2; RMS2
Search EB-eye ENSG00000150907
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (40 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
BT-474
2
E-GEOD-3529, E-GEOD-5823
KG1
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
403 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, ... (61 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-TABM-145
memory B cell
3
E-GEOD-17186, E-TABM-702, E-MEXP-2360
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
adipocyte
2
E-AFMX-5, E-MTAB-25
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
117 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-MEXP-2280, E-GEOD-16363, ... (75 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-1327, E-MEXP-2034, E-GEOD-7307
papillary thyroid carcinoma
2
E-GEOD-3467, E-GEOD-3678
benign prostatic hyperplasia
2
E-MEXP-1243, E-MEXP-2034
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
245 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, ... (33 experiments)

Factor Value U/D Experiments
ethanol
2
E-GEOD-3113, E-MEXP-2241
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
placebo
2
E-MEXP-1335, E-MEXP-1327
none
7
8
E-TABM-782, E-MEXP-1958, E-GEOD-995, E-GEOD-1724, E-MEXP-1230, ... (15 experiments)
vitamin E
1
E-MEXP-1327
ox-LDL
1
E-GEOD-5741
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-7788, E-GEOD-3325, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-10315, E-GEOD-837, E-MEXP-1273, E-GEOD-20505, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-595, E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-26495, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-17204

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.569 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM